At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
ziv-afliberceptbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
In Brief
A Phase 2 clinical trial evaluating ziv-aflibercept for Recurrent Endometrial Carcinoma. Completed, enrolled 49 participants across 67 sites.
Detailed Summary
This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with recurrent or persistent endometrial cancer. VEGF Trap may stop the growth of endometrial cancer by blocking blood flow to the tumor and by carrying tumor-killing substances directly to endometrial cancer cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Endometrial Carcinoma
CountriesUnited States
CollaboratorsGynecologic Oncology Group
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2007
Enrollment StartNov 2007
Primary CompletionJan 2013
TodayJul 2026
First PostedApr 19, 2007
Enrollment StartNov 1, 2007
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 19.2 years ago
Interventions
ziv-afliberceptbiological